</SEC-HEADER>
<SEQUENCE>1


                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  FORM 10-QSB
                                  -----------

                                   (Mark One)

     [X] QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES
                             EXCHANGE ACT OF 1934.

                 For the quarterly period ended March 31, 2007

    [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
                             EXCHANGE ACT OF 1934.

            For the transition period from __________ to __________

                        Commission File Number 000-9519

                            REGENT TECHNOLOGIES, INC.
                      ------------------------------------

       (Exact name of small business issuer as specified in its charter)


             COLORADO                                    84-0807913
     -------------------------------                  -------------------
     (State or other jurisdiction of                   (I.R.S. Employer
     incorporation or organization)                   Identification No.)


                          6727 Hillcrest Ave., Suite E
                              Dallas, Texas 75205
                    (Address of principal executive offices)

                                  214-507-9507
                          (Issuer's telephone number)

                         Regent Petroleum Corporation
                            (Former name of Issuer)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or
for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.

Yes [ ] No [X]

The number of outstanding shares of the issuer's only class of common stock as
of May 1, 2007 was 4,793,983.

Transitional Small Business Disclosure Format (check one):

Yes [ ] No [X]

Shell Company (check one):

Yes [X] No [ ]





<PAGE>
                             REGENT TECHNOLOGIES, INC.
                          (A DEVELOPMENT STAGE COMPANY)

                              INDEX TO FORM 10-QSB

                                 MARCH 31, 2007

                                                                       Page Nos.
                                                                       --------

PART I - FINANCIAL INFORMATION

  ITEM 1 - FINANCIAL STATEMENTS

    BALANCE SHEET (UNAUDITED)                                                 2
      At March 31, 2007

    STATEMENTS OF OPERATIONS (UNAUDITED)                                      3
      For the Three Months Ended March 31, 2007 and 2006
      For the Period from Inception (January 1, 1999) to
        March 31, 2007

    STATEMENTS OF CASH FLOWS (UNAUDITED)                                      4
      For the Three Months Ended March 31, 2007 and 2006
      For the Period from Inception (January 1, 1999) to
        March 31, 2007

    NOTES TO FINANCIAL STATEMENTS (UNAUDITED)                               5-6

  ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION        6-8

  ITEM 3 - CONTROLS AND PROCEDURES                                            9

PART II - OTHER INFORMATION

  ITEM 1 - LEGAL PROCEEDINGS                                                  9

  ITEM 1A - RISK FACTORS                                                   9-11

  ITEM 2 - CHANGES IN SECURITIES AND PURCHASES OF EQUITY SECURITIES          11

  ITEM 3 - DEFAULTS UPON SENIOR SECURITIES                                   11

  ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS               11

  ITEM 5 - OTHER INFORMATION                                                 11

  ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K                                  11

  SIGNATURES AND REQUIRED CERTIFICATIONS                                     11


                                       1
<PAGE>

                                    PART I

ITEM 1 - FINANCIAL STATEMENTS

                      REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                                 BALANCE SHEET
                                  (UNAUDITED)
                                 MARCH 31, 2007

<TABLE>
<CAPTION>

<S>                                                                      <C>
 CURRENT ASSETS
   Cash in bank                                                         $   82,475
   Settlements and receivable, net of $12,892
     allowance for uncollectible accounts                                        -
                                                                          ---------
Total Current Assets                                                        82,475

Property and equipment:
   Furniture and fixtures                                                    8,593
   Computer equipment                                                        2,400
                                                                         ---------
                                                                            10,993
   Less accumulated depreciation                                           (10,993)
                                                                         ---------

     Net property and equipment                                                  -
                                                                         ---------

                                                                        $   82,475
                                                                         =========

                 LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES
   Accounts payable, trade                                              $   55,439
   Accounts payable, stockholder                                            10,000
   Accrued interest payable                                                  4,583
   Acquisition liability                                                    75,000
                                                                         ---------

      Total Current Liabilities                                            145,022
                                                                         ---------

Note payable - related parties                                              55,200
                                                                         ---------

Commitments and contingencies                                                    -

STOCKHOLDERS' DEFICIT
   Preferred stock, $.10 par value, 30,000,000
     shares authorized, no shares issued and
     outstanding, no rights or privileges designated                             -
   Common stock, $.01 par value, 100,000,000
     shares authorized, 19,736,321 shares
     issued and 4,793,983 outstanding                                      197,363
   Paid-in capital in excess of par                                      3,200,785
   Accumulated deficit (including $167,896
     accumulated since reentering the development stage)                (3,515,895)
   Less treasury stock, at cost, 14,942,338 shares                               -
                                                                          ---------

      Total stockholders' deficit                                         (117,747)
                                                                          ---------

							                $   82,475
                                                                          =========


            The accompanying notes are an integral part of the financial statements.

</TABLE>

                                       2


<PAGE>
                     REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                              STATEMENT OF OPERATIONS
                FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
                        AND FOR THE PERIOD JANUARY 1, 1999
                              THROUGH MARCH 31, 2007
                                   (UNAUDITED)
<TABLE>
<CAPTION>
                    				  				        Cumulative
                                                                                     Since Re-entering
                                              For the Three Months Ended March 31,   Development Stage
                                                    2007                2006          January 1, 1999
                                                ------------        ------------        ------------
<S>                                            <C>                 <C>                 <C>
Revenues                                         $        -          $        -          $       -

Operating expenses:

  General and administrative                         17,369              10,882             242,613
  Interest                                            1,692               2,952              29,804
                                                  ---------           ---------           ---------
Operating loss                                      (19,061)            (13,844)           (272,417)
                                                  ---------           ---------           ---------

Gain on extinguishment of debt                            -               1,011             104,521
                                                  ---------           ---------           ---------
Loss from continuing operations
  before income taxes                               (19,061)            (12,823)           (167,896)

Provisions for income taxes                               -                   -                   -
                                                  ---------           ---------           ---------
Loss from operations                                (19,061)            (12,823)           (167,896)
                                                  ---------           ---------           ---------

Net loss                                            (19,061)            (12,823)           (167,896)
                                                  =========           =========           =========

Net loss per common share, basic and diluted:     $(    .00)          $(    .00)

Weighted average number of shares,
Basic and diluted                                 4,793,983          19,672,321



The accompanying notes are an integral part of the financial statements.

</TABLE>


                                       3

<PAGE>
                     REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
                             STATEMENTS OF CASH FLOWS
                 FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006
                       AND FOR THE PERIOD JANUARY 1, 1999
                            THROUGH MARCH 31, 2007
                                  (UNAUDITED)
<TABLE>
<CAPTION>
						  		   		                    Cumulative
                                                                                                 Since Re-entering
                                                          For the Three Months Ended March 31,   Development Stage
                                                                2007                2006          January 1, 1999
                                                             ------------       ------------        ------------
<S>                                                         <C>                 <C>                <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
  Net Income (Loss)                                           $( 19,061)          $( 12,823)          $(167,896)
  Adjustments to reconcile net income (loss) to net
   cash used in operating activities:
     Depreciation                                                     -                   -               3,762
     Gain from extinguishment of debt                                 -            (  1,011)           (104,521)
     Note issued for settlement expenses                              -                   -              20,000
     Common stock issued for services                                 -                   -               5,000
     Common stock issued in legal settlement                          -                   -              14,000
     Decrease in settlements and note receivable                      -                   -               4,800
     Decrease in other assets                                         -                   -               1,967
     Increase in allowance for uncollectible settlements              -                   -              79,892
     Increase (decrease) in accounts payable                      9,669               7,631              45,952
     Increase (decrease) in accounts payable, stockholder             -                   -              10,000
     Increase (decrease) in accrued liabilities                  76,692               2,952             114,319
                                                              ---------           ---------           ---------
        Net Cash Used In Operating Activities                    67,300             ( 3,251)             27,275
                                                              ---------           ---------           ---------
CASH FLOWS FROM INVESTING ACTIVITIES:
  Proceeds from stockholders                                          -                   -                   -
                                                              ---------           ---------           ---------
        Net Cash Provided By Investing Activities                     -                   -                   -

CASH FLOWS FROM FINANCING ACTIVITIES:
  Proceeds from note payable - related party                     15,000               3,000              55,200
                                                              ---------           ---------           ---------
        Net Cash Provided By Financing Activities                15,000               3,000              55,200
                                                              ---------           ---------           ---------
Net Increase (Decrease) in Cash                                  82,300                (251)             82,475
Cash At Beginning Of Period                                         175                 544                   -
                                                              ---------           ---------           ---------

Cash At End of Period                                         $  82,475           $     293           $  82,475
                                                              =========           =========           =========




           The accompanying notes are an integral part of the financial statements.

</TABLE>

                                        4
<PAGE>
                     REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
               NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

1.  DESCRIPTION OF THE BUSINESS:

General

Regent  Technologies, Inc., (the Company) formerly Regent Petroleum Corporation,
was incorporated on January 18, 1980, in the state of Colorado for the purpose
of exploration  and development of oil and gas properties in the United States.
Activities of the Company up to 1992 were primarily organizational and included
the issuance of equity capital and the acquisition of developed and undeveloped
oil and gas properties that included the formation of Earth Minerals, Inc. in
1991, which was later renamed Regent Industries, Inc. In 1992, the Company
redirected its core activities and acquired SSB Environmental, Inc. (SSB), which
was organized for the purpose of obtaining waste and landfill reclamation
contracts. Effective January 1, 1996, the Company sold 100% of Regent Industries
and 81% of its interest in SSB.  In September, 1996, the Company entered into a
license agreement for the technologies necessary to offer dialup access to the
Internet. During the fourth quarter of 1996, the Company organized Regent TEL1
Communications, Inc. as a Nevada corporation and a wholly owned subsidiary to
market its Internet products and services primarily to consumer markets.  In the
third quarter of 1997, the Company acquired ConnecTen, L.L.C. as a wholly owned
subsidiary to market its dedicated Internet access services to professionals and
corporations.  During the first quarter of 1998,the Company acquired Channel
Services, LC, to expand its telecommunications products to include wireless
telephone services.  The acquisitions of ConnecTen and Channel Services were
accounted for under the purchase method of accounting.  During the first quarter
of 1998, the Company organized Regent Digital Imaging, Inc. to offer digital
printing and prepress services with access available via the Internet. Effective
January 1, 1998, the Company in the ordinary course of business divested 100%
of its ownership in all subsidiary companies and re-entered the development
stage.

Subsidiary formation

On March 6, 2007, the Company completed the formation of a new Texas corporation
as a wholly owned subsidiary operating under the name Regent GLSC Technologies,
Inc. ("Regent GLSC").  Regent GLSC was formed to participate in the "global
life science commercialization" process by working with inventors and innovative
research teams focused on the creation of emerging medical products.  Regent
GLSC's focus is the acquisition of equity in new product development and in
future income streams derived from new products marketed domestically and
throughout the world.  Acquisition targets are research teams that show the
greatest prospect of early and high returns from commercialization of the
product(s) being developed.  Full attention is paid to the speed of regulatory
approval, to the status of the product market, and to prospects of competition
that might be encountered in the market. Specific attention is paid to investing
in product groups which have no known rival. In some cases, licensing agreements
will lead to ownership retention of the original development company. In others,
licensing agreements may lead to public stock offerings or to the complete sale
of the development company to an interested suitor.  The strategy includes
sitting on the boards of and shaping policy of the acquired interests to assure
the highest prospect of return for the shareholders of Regent GLSC and the
Registrant.

2.  INVESTMENT IN EQUITY SECURITIES

On April 17, 2007, Regent GLSC executed a stock purchase agreement in the
amount of $1,000,000.00 for the acquisition of 385,356 shares of 8% Convertible
Preferred Stock of MacuCLEAR, Inc. ("MacuCLEAR"), convertible on a non-dilutable
basis into 20% of the common stock of MacuCLEAR for a period of 24 months after
closing.  Regent GLSC acquired its interest through the payment of $200,000 cash
and the execution of a promissory note in the principal amount of $800,000. The
principal of this note is payable in two installments. The first installment of
$300,000 is due and payable on or before June 1, 2007 and the second installment
of $500,000 is due and payable on or before August 30, 2007.  As security for
payment of the obligations under the promissory note, Regent GLSC has assigned
to holder a security interest in 308,285 shares of  Convertible Preferred Stock.
Upon payment in full of the first installment, 115,607  shares of Convertible
Preferred Stock, shall be released.  The promissory note does not  bear interest
and is non-recourse to other assets of Regent GLSC or the Registrant, including
the 77,071 shares of  MacuCLEAR securities for $200,000 cash.  The  source
of the payment of $200,000 was $150,000 from the sale of the 30,000 shares of
Regent GLSC Series A Convertible Preferred Stock and $50,000 from NR Partners on
a short term promissory note secured by 35,000 shares of Convertible Preferred
Stock of MacuCLEAR.  MacuCLEAR was formed by Texas A & M University as a drug
discovery and development company focused on treating disorders of the eye.
MacuCLEAR has the exclusive license for a platform technology for preventing
the progression of Age Related Macular Degeneration ("AMD").  Specifically
MacuCLEAR has licensed a proprietary treatment for the "Dry" form of AMD
from Texas A & M University.

                                        5
<PAGE>
                     REGENT TECHNOLOGIES, INC. AND SUBSIDIARY
                          (A DEVELOPMENT STAGE COMPANY)
               NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS



3.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying financial statements have been  prepared in accordance with
accounting principles generally accepted in the United States of America. These
accounting principles were  applied on a  basis consistent  with  those of the
financial statements contained in  the Company's Annual  Report on Form 10-KSB
(Annual Report) for the year ended December 31, 2006 filed with the Securities
and Exchange Commission.  The accompanying financial statements should be read
in conjunction with the financial statements contained in the Company's Annual
Report.   In the opinion of management, all  adjustments (which  include only
normal recurring adjustments)  necessary  to present fairly  the financial
position, results of operations and cash flows of the Company for all periods
presented have been made.

Certain information and footnote disclosures normally included in financial
statements prepared in accordance with accounting principles generally accepted
in the United States of America have been condensed or omitted.  The results of
operations for the this current fiscal quarter are not necessarily indicative
of the operating results expected for any succeeding fiscal quarter or for the
fiscal year.

Development stage activities

By the end of 1998, the Company had ceased operations and had divested itself
of any interests in subsidiary companies and  effective January 1, 1999  had
re-entered the development stage.  Accordingly, all of the Company's operating
results and cash flows reported in the accompanying financial statements from
that date are considered to be those related to development  stage activities
and represent the 'cumulative  from inception' amounts  from  its development
stage activities  reported  pursuant to  Statements of  Financial  Accounting
Standards (SFAS) No. 7, Accounting and Reporting by Development Stage
Enterprises.

Management estimates

The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.

Acquisition liability

During the quarter ended March 31, 2007, the Company received $75,000 for
deposits by investors to purchase shares of Regent GLSC convertible preferred
stock under a private offering to sell 25% of the equity of Regent GLSC for
$1,250,000.  This deposit was refundable subject to the final negotiation and
acquisition of the preferred stock of MacuCLEAR, Inc.  The closing was
finalized on April 17, 2007.

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

Forward-Looking Statements

The following discussion and analysis should be read in conjunction with the
financial statements and notes thereto included elsewhere in this report on Form
10-QSB and with the annual report of Regent Technologies, Inc. ("Regent" or "We"
or the "Company") on Form 10-KSB for the fiscal year ended December 31, 2006.
This report on Form 10-QSB contains certain statements that are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933, as
amended (the "Securities Act"), and Section 21E of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"). Those statements, among other things,
include the discussions of the Company's expectations set forth below. Although
the Company believes that the expectations reflected in the forward looking
statements  are  reasonable, management can  give  no  assurance  that  such
expectations  will prove to  have been correct.  Generally, forward looking
statements relate to business plans or strategies, projected or anticipated
benefits or other consequences of such plans or strategies, or projections
involving  anticipated  revenues, expenses,  earnings, levels  of  capital
expenditures, liquidity or indebtedness, ability to raise working capital, or
other aspects of operating results or financial position. Although not always
the case, forward looking statements can be identified by the use of words
such as "believes", "expects", "intends", "projects", "anticipates",
"contemplates", or "estimates".

The following discussion and analysis should be read in conjunction with the
remainder of this Quarterly Report on Form 10-QSB including, but not limited to,
the financial statements and notes thereto included herein.

                                       6
<PAGE>

Business

Regent Technologies, Inc., a Colorado corporation, currently trades on the
"pink sheets" under the symbol "REGT".  The Company is a development stage
company and its efforts have been primarily devoted to identification of
technology for acquisition and raising capital. This discussion provides
an analysis of the Company's anticipated plan of operation for the next twelve
months.

Plan of Operation

As a development stage company, Regent has funded operations through short-term
borrowings and equity investments in order  to meet  obligations.  Our  future
operations are dependent  upon  external funding and our ability  to  increase
revenues and reduce expenses. Management believes that sufficient funding will
be available from additional related party borrowings and private placements to
meet our business  objectives  including  anticipated cash  needs for  working
capital, for a reasonable period of time.

During the quarter ended  March 31, 2007, the Registrant  initiated  a  new
business  strategy  to  create  value  for  our stockholders  by  investing in
businesses that have an intrinsic value in excess of their  stated  book value.
Key elements of our business  strategy  include  investing in  businesses with:
(1) the potential of outstanding  earning  power and  good  returns  on equity;
(2) experienced  management; and (3) a business plan which  demonstrates a high
likelihood for success in a relatively short period of time.  We  plan to enter
into each investment  with the  assumption that the  company's  management will
execute  its business  plan and  produce price appreciation of its stock  value
and our investment. However, the investment structures  that  we  utilize  will
often hedge our position in the event that the company does not execute and the
investment value declines.  The investments  will be  primarily in debt, equity
and equity-linked securities, of public and selected private companies which may
become public.

  Global life science commercialization - GLSC

Many factors are raising significant new opportunities in the development of
innovative products for dealing with human health and wellbeing.  One of the
noticeable stimulants to recent  medical innovation arises from remarkable
advances in knowledge within  the fields of biotechnology and nanotechnology.
However, perhaps the most profound force confronting the industry today is the
demographic shift that the US and other developed nations are experiencing.
Aging populations in this country, Japan and Europe in particular are expected
to double demands on medical and health-care institutions and related products
over the next decade.  A third major force, particularly behind the development
of new pharmaceuticals related to aging, is the large grouping of branded drug
patents that will be expiring in the next few years.

Drug industry analysts indicate that over the next two years, nearly half of
the industry's top drugs valued at $100 billion in sales will lose their patent
protection and not be replaced by major firms.  Declining pharmaceutical share
values have reflected that prospect and the already weak trends in branded drug
sales.  The resulting sense of urgency and dramatic escalations in the internal
costs of discovering new proprietary drugs has caused a shift in the development
strategies of major pharmaceutical firms toward hunting for new product that is
being developed  outside their laboratories.  As a  consequence,  sizeable
investment is  being  made by  these  firms into  the acquisition of promising
licenses with independent research teams throughout the country.  The Company
is focused on funding the best of these teams in both drugs and medical
technology that are in the final stages of product development and proof-of-
product testing in preparation of offering production and marketing licenses.

  Regent GLSC Technologies, Inc.

The Company  formed Regent GLSC Technologies, Inc. as a  subsidiary for the
purpose of participating in the global life science commercialization process.
The mission of Regent GLSC  is to identify  high-prospect and  high-profit
candidates in the life science industry for near-term commercialization.  The
strategy of Regent GLSC is  to secure  advantage gained  from  exceptional
opportunities emerging from new conditions in the pharmaceutical industry and
from unique developments in medical science.  Despite the sizeable funds
directed by major pharmaceutical and technology companies for the development
of new drugs and medical devices, many of the most significant advances in
those products are being made by independent and university-based research
teams.  In those instances, very attractive opportunities arise particularly
for investment groups served by entrepreneurial teams.  Most academic and
independent researchers capable of focusing on innovative work are not well
suited for capitalizing and preparing their products for either licensing or
direct marketing.  Great benefits are gained by the research team that chooses
to join forces with a funding and development group such as Regent GLSC which
is able to implement business plans and marketing strategies suited for the
medical industry.  On April 17, 2007, Regent GLSC acquired its initial entry
into the GLSC market upon execution of a stock purchase agreement for 385,356
shares of 8% Convertible Preferred Stock of MacuCLEAR, Inc. (Note 2.)


                                       7
<PAGE>

  About MacuCLEAR, Inc.

MacuCLEAR has the exclusive license for a platform technology for preventing the
progression of Age Related Macular Degeneration ("AMD") with the potential of
reversing the effect of AMD.  Specifically MacuCLEAR has licensed a proprietary
treatment for the "Dry" form of AMD.  The solution is delivered in eye drop form
to restore choroidal blood flow and control inflammation in the macula. The core
component of this novel solution has been used clinically in other applications
and is known to be safe.  Therefore, MacuCLEAR is eligible for an abbreviated
FDA approval process. AMD is the leading cause of blindness for people over the
age of 50.  AMD is the deterioration and breakdown of the macula, the central
portion of the retina responsible for  detailed vision  such as reading  and
driving.  AMD commences when blood flow in the tiny blood vessels of the macula
become restricted, a condition  known as "Dry" AMD.  The  disease can steadily
progress into "Wet" AMD, whereupon vision loss becomes imminent. Fifteen million
Americans currently have AMD, 90% of these have Dry AMD for  which there is no
present cure.  There are an estimated 1.8 Million new cases of "Dry" and 200,000
"Wet" each year.  These numbers double for  global estimates.  The total U.S.
market potential is $18 billion based on current market for treatments for the
10% who have wet AMD. The potential MacuCLEAR revenues are $1.5 billion in five
years from licensing fees, milestone payments and royalties.

MacuCLEAR is headed by an executive team of business and life science
professionals with significant industry experience.  Philip G. Ralston is the
CEO of MacuCLEAR and the President of Regent GLSC.  He is a seasoned life
science industry professional with Fortune 200, and mid-size private and public
company experience.  He has started four companies and holds 18 patents on
various products.  David A. Nelson, Chief Executive Officer of Regent GLSC and
the Registrant, is a member of the Board of Directors of MacuCLEAR with
Mr. Ralston.

As of the date of this quarterly report, there is substantial doubt regarding
our ability to continue as a going concern as we have not generated sufficient
cash flow to fund our business operations and material commitments. Our future
success and  viability, therefore, are  dependent  upon our ability to generate
capital financing.  We are  optimistic  that we will be  successful in  our new
business  operations  and  capital  raising  efforts; however,  there can be no
assurance that we will be successful in generating revenue or raising additional
capital. The failure to generate sufficient revenues or raise additional capital
may have a material and adverse effect upon the Company and our shareholders.

Financial Condition

The Company did not have revenues from operations in each of the last two fiscal
years.  The Company  is not current  on  its  trade  payables  including amounts
owed to stockholders and continues to  raise  monies  as needed through proceeds
from the sale of the Company's restricted Common Stock or from short term loans
from individuals.

The Company has borrowings under notes payable to NR Partners, a partnership
of which the President is a partner.   The notes payable are due  beginning
July 31, 2007 and bear interest at the rate of eight and one half percent per
annum. The funds have been used to pay expenses related to professional and
transfer agent fees incurred primarily to bring the Company current with its
SEC  filings.  Through  May 1, 2007, the Company  has  borrowed  a  total of
$105,200 under the notes  payable to NR Partners.  In  addition, Regent GLSC
raised $150,000 of capital through  the sale of 30,000 shares of it Series A
Convertible Preferred Stock  received  through a  Closing on  April 18, 2007.
Regent GLSC has additional closings scheduled for May 30 and August 15, 2007
with intentions to raise up to an additional $1,000,000.

The Company is not performing any product research and development at this time
and it is not expected to purchase equipment or incur significant changes in the
number of employees.

Off-Balance Sheet Arrangements

As of the date of this report, we do not have any off-balance sheet arrangements
that have or are reasonably likely  to have a current or future effect on our
financial condition, changes in  financial  condition,  revenues or  expenses,
results of operations, liquidity, capital expenditures or capital resources that
are material to investors.  The term "off-balance sheet arrangement" generally
means any transaction, agreement or other contractual arrangement to which an
entity  unconsolidated  with us is a  party, under which we have:  (i) any
obligation arising under a guarantee contract, derivative instrument or variable
interest; or (ii) a retained or contingent interest in assets transferred to
such entity or similar arrangement that serves as credit, liquidity or market
risk support for such assets.

                                        8
<PAGE>

ITEM 3 - CONTROLS AND PROCEDURES

(a)    Evaluation of disclosure controls and procedures.

The Company's principal executive and financial officers have conducted an
evaluation of the effectiveness of the Company's disclosure controls and
procedures pursuant to Rule 13a-15(b) under the Securities Exchange Act of
1934 as of the end of the period (the "Evaluation Date").  Based upon that
evaluation, the Company's principal executive and financial officers have
concluded that, as of the Evaluation Date, the Company's disclosure controls
and procedures were effective in ensuring that all material information
relating to the Company required to be filed in this quarterly report has been
made known to them in a timely manner.

(b)    Changes in internal controls.

There have been no significant changes made in the Company's internal controls
or in other factors that has or will likely materially affect internal controls
over financial reporting.


                                     PART II

ITEM 1 - LEGAL PROCEEDINGS

During 2001, stockholder David Nelson (President of the Company beginning in
2003) initiated a lawsuit against the Company and management of the Company
for issuing shares of common stock without consideration. The case was ordered
for mediation  and on  February 27, 2003, the case  was  settled with former
management concurring  that 7,331,504 shares were issued without consideration
and should be cancelled.  Also, as part of the mediation settlement, it was
agreed that certain shares previously owned by the father of then President,
Richard Straza and the Straza family members and legal entities (the Straza
Shares) would be  returned  and  cancelled  and  that the  Company would be
indemnified  against claims arising from the issuance  of the Straza Shares.
A total of approximately 16,000,000 shares were marked for cancellation.

As of May 1, 2007, the  Company through  settlements has  received stock
certificates or lost stock certificate notarized resolutions representing
a return of 15,692,338 shares, of which 750,000 shares have been cancelled
and the balance of the shares are held in treasury.  The Company plans to
continue to pursue the return of all disputed shares for cancellation.


ITEM 1A - RISK FACTORS

Risk of Limited Operating History

Regent GLSC is a newly organized venture.  Although management has
extensive experience in the industry and management of secured assets,
there can be no assurance that the Company will be profitable or that
the Company's business will be successful in the future.  To date the
Company has no revenues from operations and no assets.

Reliance on Key Personnel

The success of the Company's operations is heavily dependent upon the
continued active participation of its executive Officers and Directors.
Should they be unable or unwilling to continue active participation in
the Company's affairs, the future viability of the Company would be
materially adversely affected unless competent replacement(s) could be
promptly hired.

Capital Requirements

Without the proceeds of the Regent GLSC Offering, we will have only
minimal capital with which to provide investments and will be limited in
our operations.  If the Regent GLSC Offering does not raise a substantial
amount of funds, our  capital  may prove to  be insufficient  to permit
substantial operations to commence, other than to a very limited extent.
We may receive from the Regent GLSC Offering maximum  net proceeds of
$1,250,000, which we believe will be sufficient to implement our initial
plan of operation.  Less than the maximum amount may be obtained. If less
than the maximum financing Regent GLSC Offering is not available to us,
our activities may be materially and adversely affected.



                                        9
<PAGE>

Unspecified Investments and Acquisitions

The Company will use all of the net proceeds from the Regent GLSC Offering
and other Company Offerings to acquire existing business entities or an
equitable interest of business entities to enhance the Company's ability
to meet its business objectives.  In this regard, management of the Company
has complete authority and responsibility for evaluating and choosing the
assets for which the Company will provide investment.  Purchasers of the
Securities will not have an opportunity to evaluate for themselves all the
assets in which capital of the Company will be invested, or the terms of
such investments.   The following information will be made available to a
stockholder upon request once an asset has been acquired: (a) the specific
terms of the acquisition agreements; (b) the identity or experience of any
co-venture or development or strategic alliance partners; (c) the type or
locations of the assets; (d) the financing terms which the asset owner may
receive; (e) other relevant economic and financial data and other facts
concerning the assets; and / or (f) identity of the asset purchased.

Competition

The Company has numerous competitors in its investing operations, including
angels and venture capital companies, which may lend or invest on an unsecured,
as well as on a secured basis.  In connection with its financing of medical
research groups, competitors include numerous drug and technology companies.
The Company expects that new competitors will enter the market for acquiring
promising assets.  Some of the competitors of the Company may have greater and
more sophisticated development, financial, marketing, distribution and other
resources than the Company.  Increased competition may have a material adverse
effect on the profitability of the Company.

Risks Related to Improper Assessment of the Acquired Asset's Estimated Value

Evaluations of  research and invention  groups  are based  on best  effort
investigation of the research focus, the team strength and the potential market
prospects.   In this regard, the recovery of  the amount advanced, as well as
realization of a profit on marketing or licensing of a new product is dependent
on the initial  assessment or  appraisal of  the invention's  estimated  value.
No assurance can be given that  such appraisals  will in  any or all cases, be
accurate.  Also, since an appraisal fixes its value at a  given  point in time,
subsequent events could adversely affect  the prospect of  financial  recovery.
Such subsequent events may include  nationwide, statewide or  local  economic,
demographic,  regulatory,  medical or  other  technical  and  pharmaceutical
developments.  Denial of  FDA  approval, an  unforeseen  ill effect  of  the
formulation or unwillingness of medical practitioners to employ the new drug or
medical device could adversely affect the  value of a  particular investment.
The Company will not necessarily be able to predict with any certainty whether
any of these events will occur after an investment is made. Improper assessment
of the market value of the invention can result in reduced marketability of the
asset and resale of the asset for an amount less  than  the a mount  advanced.
Although the skill of the Company management team lead us to believe that it can
expertly identify and evaluate innovations, no assurances can be given that such
innovations will produce a profit.

Diversification Risk

The Company may not be able to diversify its asset portfolio either financially
or substantively.   If the Company does not raise  sufficient funds through the
Regent GLSC Offering or other Offerings, the  Company may  have a  small amount
of money with which to invest in product development. An investment of a smaller
sum of money will likely result in the acquisition  of fewer assets  and  less
diversification of the GLSC portfolio.  In addition, the  Company contemplates
that the majority of its  investments for  GLSC technology  will  be secured by
inventions in the medical sector.  If substantial portions of  our  investments
are secured by assets involved in medical treatment, a  downturn  in that sector
of the economy would  more greatly affect us than if our lending  and  investing
were more industrially diversified.  Adverse changes in  national  political /
regulatory action toward medical treatment or toward other sectors relating to
the medical industry in   which innovative  products are to be  marketed would
likely have an adverse impact on the profitability of the asset invested in.

Risks Associated with Operations

If expenses  of operations  exceed the  anticipated income  of operations, the
Company may be required to dispose of the assets on disadvantageous terms, if
necessary, to raise capital.  In the event operations do not generate sufficient
operating income to pay all of the operating expenses, taxes and debt service
requirements, the Company may sustain a loss of its investment.  There can be no
assurance that the Company will not incur operating deficits.

Government Regulation

Development of new drugs and  medical  procedures  are  subject to  extensive
regulation, supervision and  licensing under various federal, state and local
statutes, ordinances and regulations.  These  statutes prescribe, among  other
things, extent of testing and proof required to market a medical device or drug.
Governmental regulators have broad discretionary authority to refuse to grant a
license or to suspend or revoke any or all existing licenses of licensees under
common control if it is determined that any such licensee has violated  any law
or regulation or that the management of any  such licensee is not  suitable to



                                        10
<PAGE>

bring such a product to market.  In addition, there  can be no  assurance that
additional state or federal statutes or regulations will not be enacted at some
future date which could inhibit the team's  ability to  grow a  product market,
conduct further research, bring  new products  to market, or  prohibit or more
stringently regulate the sale of certain goods, any of which could significantly
adversely affect the Company's prospects.

Failure to Obtain Government Approvals

The treatment planned by MacuCLEAR is subject to extensive government regulation
in the U.S. and in the foreign countries.  Unless an exemption applies, without
regulatory approval and clearance from the FDA, revenues will be significantly
limited.

Products Are Subject to Recall

Any of  the products  planned by MacuCLEAR  may be found to have deficiencies or
defects in design or manufacture. The FDA or similar governmental authorities in
other countries have the authority to require the  recall of any such defective
product.  A government-mandated or voluntary recall  could occur as a result of
component failures, manufacturing errors or design defects.  MacuCLEAR does not
maintain insurance to cover losses incurred as a result of product recalls. Any
product recall would divert managerial and financial resources and negatively
affect our financial performance.

Failure to Comply With Applicable Government Regulations

MacuCLEAR is subject to numerous government regulations relating to, among other
things, its ability to sell its  products, and  non-compliance could  result in
fines and penalties, civil or criminal  charges, disruption of manufacturing or
distribution, or the withdrawal of approvals for its products.


ITEM 2 - CHANGES IN SECURITIES AND PURCHASES OF EQUITY SECURITIES

On April 18, 2007, Regent GLSC Technologies, Inc. ("Regent GLSC"), a wholly
owned subsidiary of the Registrant, accepted purchase agreements in a total
amount of $150,000 received from 4 purchasers to its private offering of shares
of Series A Convertible Preferred Stock (the "Convertible Preferred Stock").
Pursuant to the accepted purchase agreements, the subscribers purchased through
a Preferred Stock Purchase Agreement 30,000 shares of Regent GLSC's Convertible
Preferred Stock at $5.00 per share. The stock was sold under a private placement
offering to sell 25% of the equity of Regent GLSC for $1,250,000.00. Regent GLSC
is continuing to raise capital through the sale of shares of the Convertible
Preferred Stock in $50,000 units. Each unit is convertible into 10,000 shares of
common stock of Regent GLSC plus 0.5% of the outstanding shares of common stock
of MacuCLEAR, non-dilutable for a period of 24 months after closing.  Also, the
Registrant and Regent GLSC are exploring other avenues for raising capital.


ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

Extinguishment of debt

On September 26, 2006, the Company entered into a settlement agreement whereby
it agreed to issue 64,000 common stock shares, with a fair value of $3,840,
to fully pay and settle its $64,000  note payable  and $24,736 of  related
accrued interest.  The difference between the fair value of the common stock
shares to be issued and the carrying  value of the note payable and accrued
interest has been  recognized as  a gain on extinguishment of  debt in  the
accompanying statement of operations.  In addition, $1,011 was recognized as
gain following an  adjustment to a previously expensed account payable.

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

          None

ITEM 5 - OTHER INFORMATION

          None

ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits

          Exhibit 31.1 Certification
          Exhibit 32.1 Certification

(b) Reports filed on Form 8-K

    On March 20, 2007, the Company filed a Current Report on Form 8-K
    reporting a material definitive agreement whereby the Company completed
    the formation of a new Texas corporation as a wholly owned subsidiary
    operating under the name Regent GLSC Technologies, Inc. ("Regent GLSC"),
    and the execution of its initial purchase and sale agreement in the amount
    of $50,000.00 for the subscription by an investor to purchase 10,000 shares
    of Regent GLSC preferred stock under a private placement offering to sell
    25% of the equity of Regent GLSC for $1,250,000.

    On April 26, 2007, the Company filed a Current Report on Form 8-K
    reporting that Regent GLSC Technologies, Inc. ("Regent GLSC"), a wholly
    owned subsidiary of the Registrant, accepted purchase agreements in a total
    amount of $150,000 received from 4 purchasers of its private offering of
    shares of Series A Convertible Preferred Stock (the "Convertible Preferred
    Stock") at $5.00 per share.  The Company also reported that Regent GLSC
    executed a stock purchase agreement in the amount of $1,000,000.00 for the
    acquisition of 385,356 shares of Convertible Preferred Stock of MacuCLEAR,
    Inc. ("MacuCLEAR"), convertible on a non-dilutable basis into 20% of the
    common stock of MacuCLEAR for a period of 24 months after closing.


                               SIGNATURE

In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                                      REGENT TECHNOLOGIES, INC.

Dated: May 14, 2007              By: /s/ David A. Nelson
                                      ---------------------------------------
                                      David A. Nelson, Chief Executive Officer,
                                      Principal Accounting Officer


                                        11